Education
About Us
Working with TipRanks
Follow Us
Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
FHTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.86 - $10.25
Previous CloseN/A
Volume24.60K
Average Volume (3M)147.06K
Market Cap
$244.69M
Enterprise Value$354.51M
Total Cash (Recent Filing)$55.45M
Total Debt (Recent Filing)$37.13M
Price to Earnings (P/E)―
Beta3.04
Next Earnings
May 12, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding55,612,240
10 Day Avg. Volume101,541
30 Day Avg. Volume147,064
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.83
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.68
Enterprise Value/Ebitda-3.62
Forecast
1Y Price Target
$11.80Price Target Upside168.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Foghorn Therapeutics News
PremiumCompany Announcements
Foghorn Therapeutics Reports Progress and Financial Stability
PremiumStock Analysis & Ideas
Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks
PremiumCompany Announcements
Foghorn Therapeutics Advances Drug Development in Oncology
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe analyst expects positive data from the ongoing Phase I trial of FHD-909, with anticipated good tolerability and promising response rates at therapeutically relevant doses.
Strategic CollaborationFoghorn continues to progress its strategic collaboration with Lilly for FHD-909.
Bears Say
Financial PerformanceFoghorn reported Q4 collaboration revenue of $3M below the $10M estimate.
---
Ownership Overview
1.32% Insiders
10.98% Mutual Funds
45.40% Other Institutional Investors
37.07% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FHTX FAQ
What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $3.86 and its highest was $10.25 in the past 12 months.
What is Foghorn Therapeutics’s market cap?
Foghorn Therapeutics’s market cap is $244.69M.
When is Foghorn Therapeutics’s upcoming earnings report date?
Foghorn Therapeutics’s upcoming earnings report date is May 12, 2025 which is in 60 days.
How were Foghorn Therapeutics’s earnings last quarter?
Foghorn Therapeutics released its earnings results on Mar 06, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.313 by $0.083.
Is Foghorn Therapeutics overvalued?
According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued.
Does Foghorn Therapeutics pay dividends?
Foghorn Therapeutics does not currently pay dividends.
What is Foghorn Therapeutics’s EPS estimate?
Foghorn Therapeutics’s EPS estimate is -0.19.
How many shares outstanding does Foghorn Therapeutics have?
Foghorn Therapeutics has 55,612,240 shares outstanding.
What happened to Foghorn Therapeutics’s price movement after its last earnings report?
Foghorn Therapeutics reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.313. Following the earnings report the stock price went up 0.444%.
Which hedge fund is a major shareholder of Foghorn Therapeutics?
Currently, no hedge funds are holding shares in FHTX
---
Foghorn Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.80 (168.18% Upside)
$11.80 (168.18% Upside)
Hedge Fund Trend
Increased
By 227.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.3%
Last 30 Days ▲ 258.1%
Last 30 Days ▲ 258.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.80%
12-Months-Change
Fundamentals
Return on Equity
322.49%
Trailing 12-Months
Asset Growth
60.32%
Trailing 12-Months
Company Description
Foghorn Therapeutics
Foghorn Therapeutics (FHTX) is a biotechnology company focused on discovering and developing a new class of medicines targeting chromatin regulatory proteins. By leveraging their proprietary Gene Traffic Control platform, Foghorn Therapeutics aims to treat a wide range of diseases, including cancer. The company is based in the United States and operates within the healthcare and biotechnology sectors.
---
FHTX Stock 12 Month Forecast
Average Price Target
$11.80
▲(168.18% Upside)
Technical Analysis
Best Analysts Covering FHTX
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-10.63%
reiterated a buy rating 6 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -10.63% per trade.
---